CD4-directed chimeric antigen receptor engineered T-cells (Icell Gene)

N/A

Report date: 2022/09/02 20:00:31

Base Information

Drug NameCD4-directed chimeric antigen receptor engineered T-cells (Icell Gene)
Drug Alias NameCD4指导的嵌合抗原受体工程化T细胞-Stony Brook University School of MedicineCD4CAR (Icell Gene)
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD4
TargetsT-cell surface antigen CD4
Therapy Area/IndicationsLymphoma, T-CellLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesStony Brook University School Of MedicineIcell Gene Therapeutics (Int'L) LtdUniversity Of Louisville
China Registration ClassN/A

Develop Information

Active CompaniesiCell Gene Therapeutics LLC
Inactive CompaniesN/A
Active IndicationsLymphoma, T-CellLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A